{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:41:50Z","timestamp":1792104110497,"version":"4.4.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immunotherapy with T-cells expressing bispecific T-cell engagers (ENG T-cells) is a promising approach to improve the outcomes for patients with recurrent\/refractory acute myeloid leukemia (AML). However, similar to T-cells expressing chimeric antigen receptors (CARs), their antitumor activity is limited in the setting of chronic antigen stimulation. We therefore set out to explore whether transgenic expression of IL15 improves the effector function of ENG T-cells targeting CD123-positive AML. T-cells expressing CD123-specific ENG (CD123-ENG) \u00b1 IL15 were generated by retroviral transduction from peripheral blood T cells from healthy donors or patients with AML. In this study, we characterized in detail the phenotype and effector functions of ENG T-cell populations <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. IL15-expressing CD123-ENG (CD123-ENG.IL15) T-cells retained their antigen-specificity and effector function in the setting of chronic antigen exposure for more 30 days of coculture with AML blasts in contrast to CD123-ENG T-cells, whose effector function rapidly eroded. Furthermore, CD123-ENG.IL15 T-cells remained in a less differentiated state as judged by a high frequency of na\u00efve\/memory stem T-cell-like cells (CD45RA<jats:sup>+<\/jats:sup>CCR7<jats:sup>+<\/jats:sup>\/CD45RO<jats:sup>\u2212<\/jats:sup>CD62L<jats:sup>+<\/jats:sup> cells) without evidence of T-cell exhaustion. Single cell cytokine profiling using IsoPlexis revealed enhanced T-cell polyfunctionality of CD123-ENG.IL15 T-cells as judged by effector cytokine production, including, granzyme B, IFN-\u03b3, MIP-1\u03b1, perforin, TNF-\u03b1, and TNF-\u03b2. <jats:italic>In vivo<\/jats:italic>, CD123-ENG.IL15 T-cells exhibited superior antigen-specific anti-AML activity and T-cell persistence in both peripheral blood and tissues (BM, spleens, and livers), resulting in a significant survival advantage in one AML xenograft model and two autologous AML PDX models. In conclusion, we demonstrate here that the expansion, persistence, and anti-AML activity of CD123-ENG T-cells can be significantly improved by transgenic expression of IL15, which promotes a na\u00efve\/TSCM-like phenotype. However, we also highlight that targeting a single tumor antigen (CD123) can lead to immune escape, reinforcing the need to develop approaches to target multiple antigens. Likewise, our study demonstrates that it is feasible to evaluate autologous T cells in AML PDX models, which will be critical for future preclinical evaluations of next generation AML-redirected T-cell therapies.<\/jats:p>","DOI":"10.3389\/fimmu.2022.880108","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T05:48:50Z","timestamp":1652075330000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models"],"prefix":"10.3389","volume":"13","author":[{"given":"Hong","family":"Mu-Mosley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Ostermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muharrem","family":"Muftuoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abishek","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Challice L.","family":"Bonifant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireya Paulina","family":"Velasquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Gottschalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11864-017-0456-2","article-title":"Treatment of Relapsed\/Refractory Acute Myeloid Leukemia","volume":"18","author":"Bose","year":"2017","journal-title":"Curr Treat Options Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse Large B-Cell Lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00697","article-title":"CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions","volume":"10","author":"Mardiana","year":"2020","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.3390\/ijms22041944","article-title":"Emerging Immunotherapy for Acute Myeloid Leukemia","volume":"22","author":"Tabata","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.116","article-title":"CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia","volume":"24","author":"Bonifant","year":"2016","journal-title":"Mol Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.156","article-title":"Engager T Cells: A New Class of Antigen-Specific T Cells That Redirect Bystander T Cells","volume":"23","author":"Iwahori","year":"2015","journal-title":"Mol Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"27130","DOI":"10.1038\/srep27130","article-title":"T Cells Expressing CD19-Specific Engager Molecules for the Immunotherapy of CD19-Positive Malignancies","volume":"6","author":"Velasquez","year":"2016","journal-title":"Sci Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T Cells Secreting BiTEs Circumvent Antigen Escape Without Detectable Toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0171","article-title":"CD28 and 41BB Costimulation Enhances the Effector Function of CD19-Specific Engager T Cells","volume":"5","author":"Velasquez","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1498","article-title":"IL15 and T-Cell Stemness in T-Cell-Based Cancer Immunotherapy","volume":"75","author":"Pilipow","year":"2015","journal-title":"Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0376","article-title":"Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Ralpha2-CAR T Cells But Results in Antigen Loss Variants","volume":"5","author":"Krenciute","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 Enhances CAR-T Cell Antitumor Activity by Reducing Mtorc1 Activity and Preserving Their Stem Cell Memory Phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.75","article-title":"Engineering CD19-Specific T Lymphocytes With Interleukin-15 and a Suicide Gene to Enhance Their Antilymphoma\/Leukemia Effects and Safety","volume":"24","author":"Hoyos","year":"2010","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/s41598-018-38258-z","article-title":"A Novel Luciferase-Based Assay for the Detection of Chimeric Antigen Receptors","volume":"9","author":"Gopalakrishnan","year":"2019","journal-title":"Sci Rep"},{"key":"B15","article-title":"Cytotoxicity Assays: In Vitro Methods to Measure Dead Cells","volume-title":"Assay Guidance Manual","author":"Riss","year":""},{"key":"B16","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.ccell.2017.11.003","article-title":"Synthetic Lethality of Combined Bcl-2 Inhibition and P53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy","volume":"32","author":"Pan","year":"2017","journal-title":"Cancer Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801540","article-title":"Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy","volume":"379","author":"Muftuoglu","year":"2018","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"12388","DOI":"10.1038\/s41598-021-91816-w","article-title":"Extended Live-Cell Barcoding Approach for Multiplexed Mass Cytometry","volume":"11","author":"Muftuoglu","year":"2021","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-9773-2_19","article-title":"Single-Cell Multiplexed Proteomics on the IsoLight Resolves Cellular Functional Heterogeneity to Reveal Clinical Responses of Cancer Patients to Immunotherapies","volume":"2055","author":"Liu","year":"2020","journal-title":"Methods Mol Biol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1172\/JCI135754","article-title":"Human CD83-Targeted Chimeric Antigen Receptor T Cells Prevent and Treat Graft-Versus-Host Disease","volume":"130","author":"Shrestha","year":"2020","journal-title":"J Clin Invest"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-541235","article-title":"Invariant NKT Cells With Chimeric Antigen Receptor Provide a Novel Platform for Safe and Effective Cancer Immunotherapy","author":"Heczey","year":"2014","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2016.025","article-title":"Redirecting T Cells to Glypican-3 With 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity","volume":"28","author":"Li","year":"2017","journal-title":"Hum Gene Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.05.024","article-title":"Treatment of Acute Myeloid Leukemia With T Cells Expressing Chimeric Antigen Receptors Directed to C-Type Lectin-Like Molecule 1","volume":"25","author":"Tashiro","year":"2017","journal-title":"Mol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"101104","DOI":"10.1016\/j.beha.2019.101104","article-title":"How Close Are We to CAR T-Cell Therapy for AML","volume":"32","author":"Gill","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21745","article-title":"CD123 Expression Levels in 846 Acute Leukemia Patients Based on Standardized Immunophenotyping","volume":"96","author":"Bras","year":"2019","journal-title":"Cytometry B Clin Cytom"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.01.004","article-title":"CD123 as a Therapeutic Target Against Malignant Stem Cells","volume":"34","author":"Sugita","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1128\/mcb.7.3.1101-1110.1987","article-title":"Six Distinct Nuclear Factors Interact With the 75-Base-Pair Repeat of the Moloney Murine Leukemia Virus Enhancer","volume":"7","author":"Speck","year":"1987","journal-title":"Mol Cell Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3468","article-title":"IL15 by Continuous Intravenous Infusion to Adult Patients With Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion","volume":"25","author":"Conlon","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028332","article-title":"First-Inhuman Trial of rhIL-15 and Haploidentical Natural Killer Cell Therapy for Advanced Acute Myeloid Leukemia","volume":"3","author":"Cooley","year":"2019","journal-title":"Blood Adv"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192203","article-title":"Optimized Gene Engineering of Murine CAR-T Cells Reveals the Beneficial Effects of IL-15 Coexpression","volume":"218","author":"Lanitis","year":"2020","journal-title":"J Exp Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0293","article-title":"Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma","volume":"8","author":"Batra","year":"220","journal-title":"Cancer Immunol Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.226","article-title":"Cord Blood NK Cells Engineered to Express IL-15 and a CD19-Targeted CAR Show Long-Term Persistence and Potent Antitumor Activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003894","article-title":"Engineering CAR-NK Cells to Secrete IL-15 Sustains Their Anti-AML Functionality But Is Associated With Systemic Toxicities","volume":"9","author":"Christodoulou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0263","article-title":"Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models","volume":"7","author":"Mata","year":"2017","journal-title":"Cancer Discov"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-241398","article-title":"IL-7 and IL-21 are Superior to IL-2 and IL-15 in Promoting Human T Cell-Mediated Rejection of Systemic Lymphoma in Immunodeficient Mice","volume":"115","author":"Markley","year":"2010","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nm.4241","article-title":"T Memory Stem Cells in Health and Disease","volume":"23","author":"Gattinoni","year":"2017","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0633-5","article-title":"Beta Cell-Specific CD8(+) T Cells Maintain Stem Cell Memory-Associated Epigenetic Programs During Type 1 Diabetes","volume":"21","author":"Abdelsamed","year":"2020","journal-title":"Nat Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T Cells Overcome Challenges of Specificity, Heterogeneity, and Persistence in Treating Glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci Transl Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd8836","article-title":"SynNotch CAR Circuits Enhance Solid Tumor Recognition and Promote Persistent Antitumor Activity in Mouse Models","volume":"13","author":"Hyrenius-Wittsten","year":"2021","journal-title":"Sci Transl Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1786","article-title":"Transient Rest Restores Functionality in Exhausted CAR-T Cells Through Epigenetic Remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 Augments Antitumor Activity and Promotes a Stem-Cell Memory Subset in Tumor-Specific T Cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006921","article-title":"CLEC12A and CD33 Coexpression as a Preferential Target for Pediatric AML Combinatorial Immunotherapy","volume":"137","author":"Willier","year":"2021","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01109-w","article-title":"A Modular and Controllable T Cell Therapy Platform for Acute Myeloid Leukemia","volume":"35","author":"Benmebarek","year":"2021","journal-title":"Leukemia"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441","article-title":"CD22-Targeted CAR T Cells Induce Remission in B-ALL That Is Naive or Resistant to CD19-Targeted CAR Immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the Antigen Density Requirement for CAR T-Cell Activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00262","article-title":"A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy","volume":"10","author":"Epperly","year":"2020","journal-title":"Front Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T Cells for Treatment of Relapsed\/Refractory Acute Myelogenous Leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.880108\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T05:48:54Z","timestamp":1652075334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.880108\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2022.880108"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.880108","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,9]]},"article-number":"880108"}}